Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002200445 | SCV002351652 | likely benign | Glycine encephalopathy | 2025-01-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002260716 | SCV002540396 | uncertain significance | not provided | 2024-05-19 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004045593 | SCV004876277 | uncertain significance | Inborn genetic diseases | 2023-03-08 | criteria provided, single submitter | clinical testing | The c.166C>T (p.L56F) alteration is located in exon 1 (coding exon 1) of the GLDC gene. This alteration results from a C to T substitution at nucleotide position 166, causing the leucine (L) at amino acid position 56 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |